Abstract | BACKGROUND AND PURPOSE: EXPERIMENTAL APPROACH: In a large-scale screening test, we found that quinoclamine was a novel NF-kappaB inhibitor. The global transcriptional profiling of quinoclamine in HepG2 cells was therefore analysed by transcriptomic tools in this study. KEY RESULTS: CONCLUSION AND IMPLICATIONS:
|
Authors | W-Y Cheng, J-C Lien, C-Y Hsiang, S-L Wu, C-C Li, H-Y Lo, J-C Chen, S-Y Chiang, J-A Liang, T-Y Ho |
Journal | British journal of pharmacology
(Br J Pharmacol)
Vol. 157
Issue 5
Pg. 746-56
(Jul 2009)
ISSN: 1476-5381 [Electronic] England |
PMID | 19422389
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- I-kappa B Proteins
- NF-kappa B
- NFKBIA protein, human
- Naphthoquinones
- RELA protein, human
- Transcription Factor RelA
- NF-KappaB Inhibitor alpha
- Glucuronosyltransferase
- 2-amino-3-chloro-1,4-naphthoquinone
|
Topics |
- Antineoplastic Agents
(pharmacology)
- Apoptosis
(drug effects, genetics)
- Cell Cycle
(drug effects, genetics)
- Cell Line, Tumor
- Cell Survival
(drug effects)
- Dose-Response Relationship, Drug
- Gene Expression Profiling
(methods)
- Gene Expression Regulation
(drug effects)
- Gene Regulatory Networks
- Glucuronosyltransferase
(genetics)
- Humans
- I-kappa B Proteins
(metabolism)
- NF-KappaB Inhibitor alpha
- NF-kappa B
(antagonists & inhibitors, genetics, metabolism)
- Naphthoquinones
(pharmacology)
- Oligonucleotide Array Sequence Analysis
- Phosphorylation
- Protein Transport
- Transcription Factor RelA
(metabolism)
- Transfection
|